Lynparza (olaparib), a product of Fortune 500 pharmaceutical firm Merck and Fortune 500 Europe company AstraZeneca, showed meaningful improvements in overall survival in people with germline BRCA-mutated (gBRCAm), HER2-negative high-risk early breast cancer, 2024 clinical trial data suggest.
Jaime Grajales Benjumea—Getty Images
[matched_con] Source link
BBC Sophie Harvey admitted to concealing the birth of her child The trial of a woman accused of illegally aborting her baby collapsed due to [more…]
Molineux, 17:30 GMT I usually get a bit of feedback on social media when I predict a Manchester United defeat but it has been very [more…]
Unlock the Editor’s Digest for free Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. France’s new prime minister François [more…]
A couple of months ago, we saw the Sony WH-1000XM4 drop to $129.99, which was an absolute steal for the last-gen noise-canceling headphones. That deal [more…]
[matched_con] Source link
Disclosure: This article does not represent investment advice. The content and materials featured on this page are for educational purposes only. Ex-Wall Street trader forecasts [more…]
+ There are no comments
Add yours